Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CJ-40010 EV71 vaccine B
- Development stage
- Unknown
- Lead developer
- CJ CheilJedang
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CJ-40010 EV71 vaccine B is a biological vaccine candidate developed by CJ CheilJedang Corp. It is a monovalent component of the CJ-40010 bivalent vaccine program, which is designed to protect against Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16). This specific component targets EV71. The vaccine has undergone Phase 1 clinical testing to evaluate its safety and immunogenicity in healthy adult subjects.
- Other names
- CJ-40010 EV71 vaccine BCJ40010 EV71 vaccine BCJ 40010 EV71 vaccine B
Beyond the preview
Go deeper on CJ-40010 EV71 vaccine B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CJ-40010 EV71 vaccine B.